Kevzara fails in PhIII COVID-19 trial
Sanofi and Regeneron do not anticipate carrying out further research on Kevzara in COVID-19
Read More
Tag: sarilumab
Sanofi, Regeneron pull plug on Kevzara COVID-19 trial
The drug failed to show any significant benefit in patient requiring mechanical ventilation
Read More
SMC endorses five new therapies for NHS Scotland
Scottish cost regulators have approved funding for five new therapies on the NHS, offering new treatment options for a range of conditions.
Read More
Final NICE nod for Sanofi’s Kevzara
The National Institute for Health and Care Excellence has issued final guidance backing Sanofi’s Kevzara as a new treatment option for adults with severe, active rheumatoid arthritis (RA).
Read More
Sanofi’s Kevzara will be funded for NHS use
Some patients with rheumatoid arthritis living in England and Wales should get ‘routine’ NHS access to Sanofi’s Kevzara after cost regulators issued draft guidelines deeming the drug cost effective.
Read More
Sanofi, Regeneron’s biologic gets EU nod for rheumatoid arthritis
Sanofi and Regeneron’s Kevzara has been approved by European regulators to treat moderately to severely active rheumatoid arthritis (RA) in adult patients.
Read More
Green light for Sanofi, Regeneron’s Kevzara
Sanofi and Regeneron’s Kevzara has been cleared in the US to treat moderately to severely active rheumatoid arthritis (RA) in adult patients.
Read More
FDA rejects Sanofi/Regeneron’s sarilumab
US regulators are refusing to approve Sanofi and Regeneron’s sarilumab to treat patients with rheumatoid arthritis until certain manufacturing issues are addressed.
Read More
EU review for Regeneron/Sanofi’s RA biologic
European regulators have agreed to review Regeneron and Sanofi’s application to market the biologic sarilumab as a treatment for rheumatoid arthritis.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
